These results are derived from a global review of pharma’s corporate reputation (conducted November 2016 to early-February 2017).
This report is based on the opinions of 98 Latin-American patient groups, from Argentina (10), Bolivia (2), Brazil (21), Chile (8), Colombia (8), Costa Rica (6), Cuba (1), the Dominican Republic (1), Ecudaor (2), Guatemala (2), Mexico (27), Panama (1), Peru (2), Uruguay (1), Venezuela (4).
20 specialised in cancer; 9 in neurological conditions; 7 in haemophilia; and other specialties.
15 pharma companies are included in this 2016 Latin-America analysis:
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly (Lilly)
- Janssen (Pharmaceutical companies of Johnson & Johnson)
- Merck & Co
The 15 companies were chosen because a minimum of 17 Latin-American patient groups declared familiarity with each one.
[On patient-group relations …]
(“First, stop calling people ‘patients’, as that term in itself indicates a relationship of subordination, and definition of a person by their health condition, and not as a rights holder. It is a term that should change globally.”)
- How the pharma industry’s corporate reputation compares with that of other healthcare industries.
- How the pharma industry’s corporate reputation has changed over the past five years.
- How good or bad the pharma industry is at various activities of relevance to patients and patient groups.
7 indicators show the corporate reputation of individual pharma companies:
- Patient centricity.
- Information for patients.
- Patient safety.
- Usefulness of products.
- Patient-group relationships (new for 2016).
- In 2016, 52.1% of Latin-American patient groups thought that the pharma industry had an “Excellent” or “Good” corporate reputation (37.9% of patient groups worldwide thought the same).
- Latin-American patient groups in 2016 were, on the whole, positive about many of the pharma industry's activities. Some 70% described pharma as “Excellent” or “Good” at being innovative; 69% stated the same about pharma’s ability to produce high-quality products; and 57% thought pharma “Excellent” or “Good” at ensuring patient safety.
- However, only 23% of Latin-American patient groups in 2016 stated that pharma was “Excellent” or “Good” at providing access to clinical trials; and only 18% believed the industry fair in its pricing policies (although the latter figure was still higher than that reported in 2016 by patient groups from most other countries/regions—with the exception of those from Greece and Canada).
PHARMA COMPANIES and LATIN-AMERICAN PATIENT GROUPS
The company with which Latin-American patient groups were most familiar in 2016 was Novartis (54% of the 98 respondent Latin-American patient groups expressed themselves familiar with the company).
INDIVIDUAL COMPANY FINDINGS—LATIN AMERICA
- AbbVie ranked overall 1st in 2016 for corporate reputation among the 15 pharma companies, when judged by Latin-American patient groups. AbbVie also ranked 1st for four of the seven indicators of corporate reputation: patient centricity; patient information; integrity; and patient-group partnerships.
- Novartis ranked 1st for three of the seven indicators of corporate reputation: patient safety; high-quality products; and transparency.
HIGHS and LOWS—LATIN AMERICA
- Pharma companies’ PCRIs among Latin-American patient groups familiar with each company, 2016 v. 2015: ordered according to the difference between the PCRI values for the two years (high to low)
- The Patient Corporate Reputation Index (PCRI) standardises PatientView’s ranking data, to take into account the different numbers of companies included in country/therapy analyses. The ranking is from 0 to 1, with 1 as the best (the highest) rank.
- If the Latin-American corporate-reputation results for 2016 (15 pharma companies analysed) are compared with those of 2015 (13 pharma companies analysed) using a standardised index—the Patient Corporate Reputation Index (PCRI)—findings show that the biggest jump up the Latin-American rankings 2015-2016, was for:
- AbbVie—which signifcantly outperformed in 2016 its respective rankings among Latin-American patient groups in 2015.
Latin-American patient-group relationships with 15 pharma companies.
Industry-wide findings from Latin-American patient groups.
Latin-American patient groups on improving corporate reputation.
Rankings of the 15 pharma companies among Latin-American patient groups FAMILIAR with them.
Positioning of the 15 pharma companies among PARTNER Latin-American patient groups.
Profiles of the 15 pharma companies.
Comments from respondent Latin-American patient groups.
Profile of the 98 respondent Latin-American patient groups.
Charts and tables for each of the 15 pharma companies:
- The company’s best indicators among Latin-American patient groups familiar with the company, 2016.
- Number of Latin-American patient groups claiming familiarity with the company, 2016.
- Number of Latin-American patient groups saying they had a working relationship with the company, 2016.
- Profile of the Latin-American patient groups familiar with the company: specialities and geographic remit.
- Percentage of the Latin-American patient groups that worked with the company—but which also worked with other companies, 2016.
- The company’s average score for the seven indicators of corporate reputation among Latin-American patient groups familiar with the company, 2016 v. 2015.
- The company’s scores among Latin-American patient groups familiar with the company, and which worked with the company, for each of the seven indicators of corporate reputation, 2016.
- The company’s overall rankings for corporate reputation among patient groups familiar with the company: Latin America v. worldwide.
- The company’s positioning for corporate reputation among patient groups which worked with the company: Latin America v. worldwide. All 2016.
- The company’s rankings among patient groups for the seven indicators of corporate reputation, 2016: Latin America v. worldwide; familiar with v. worked with.
- Performance of the company at corporate reputation in different therapy areas, compared with its own Latin-American average, 2016
- The company’s Patient Corporate Reputation Index (PCRI), Latin America v. worldwide, 2016.